IPO Plus

NSE · SANOFI

Sanofi India Limited

3413.1
₹7,805 Cr market cap
P/E
28.81
EPS
₹142.04
Book value
₹325.74
ROE
40.6%
ROCE
54.17%
Debt / equity
0.02

Revenue & net profit by period

Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.

0507101515222030Sep 24Dec 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26
Revenue (₹ Cr) Net profit (₹ Cr)

Latest period: revenue ₹472 Cr with net profit ₹103 Cr — a 21.72% net margin, versus 14.7% the period before.

Shareholding

As of 2026-06-30

60.4%
promoter holding
  • Promoter60.4%
  • Public14.04%
  • FII5.69%
  • DII19.86%

80,005 shareholders on record

Promoter holding trend

Each disclosed period, oldest to newest

60.4%60.4%Sep 24Jun 26

52-week position

Where the current price sits in its yearly band

305434135925

The band spans 1.94× from low to high.

Risk flags

Derived from disclosed data

No flags raised by the data.

Peer comparison

Pharmaceuticals - Multinational · ranked #2 of 6 by market cap · medians across 4 industry peers

P/E
28.81vs 153.05 peer med
P/B
12.56vs 8.77 peer med
ROE %
40.6vs 28.82 peer med
Margin %
vs 23.16 peer med
CompanyMkt capP/EP/BROEMargin
Glaxosmithkline Pharmaceuticals Ltd.₹44,264 Cr159.3219.5245.69%27.11%
Sanofi India Limited(this company)₹7,861 Cr76.6110.4842.11%20.53%
Novartis India Ltd.₹3,960 Cr156.784.8411.39%26.38%
Pfizer Ltd.₹1,361 Cr108.915.1819.78%19.94%
Abbott India Limited₹464 Cr149.3112.3537.86%13.6%

AI analysis

AI-generated · google/gemini-2.5-flash

Sanofi India Limited has a market capitalization of Rs 7863 Cr. The company reported a revenue of Rs 1857.1 Cr and an EPS of 142.04. Its 52-week high is Rs 5955 and the 52-week low is Rs 3054.

Positives

  • +The company has a low debt-to-equity ratio of 0.02.
  • +Return on Capital Employed (ROCE) is high at 52.41%.
  • +Return on Equity (ROE) is 40.6%.

Negatives

  • Revenue decreased from Rs 510.8 Cr in Mar 2024 to Rs 463.5 Cr in Jun 2024.
  • Net profit decreased from Rs 136.6 Cr in Mar 2024 to Rs 103.2 Cr in Jun 2024.
  • Promoter shareholding in June 2026 is 60.3961, compared to higher figures in prior periods (no prior data in JSON).

Financial performance

In the latest reported annual performance for Mar 2026, the company recorded a revenue of Rs 472.3 Cr and a net profit of Rs 102.6 Cr. Over the preceding four quarters, from Mar 2025 to Dec 2025, annual revenue reached Rs 1857.1 Cr. Quarterly revenues have varied, with Rs 514.9 Cr in Dec 2024 and Rs 524 Cr in Sept 2024. Quarterly net profit stood at Rs 91.3 Cr in Dec 2024.

Profitability & returns

The company’s Return on Equity (ROE) is 40.6% and Return on Capital Employed (ROCE) is 52.41%. The Earnings Per Share (EPS) is reported at 142.04. Over the annual periods up to Mar 2026, the net profit for Mar 2026 was Rs 102.6 Cr, following Rs 61.7 Cr in Dec 2025 and Rs 76 Cr in Sept 2025.

Balance sheet

The company maintains a low debt-to-equity ratio of 0.02. The book value per share is Rs 325.74. The company has no reported pledges against promoter holdings.

Ownership & pledges

Public shareholders account for 14.0449% of the shares. There are no shares pledged by the promoters.

Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.

How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.

Back to Sanofi India Limitedshare price & fundamentals

Telegram App